JP2016130266A5 - - Google Patents

Download PDF

Info

Publication number
JP2016130266A5
JP2016130266A5 JP2016083344A JP2016083344A JP2016130266A5 JP 2016130266 A5 JP2016130266 A5 JP 2016130266A5 JP 2016083344 A JP2016083344 A JP 2016083344A JP 2016083344 A JP2016083344 A JP 2016083344A JP 2016130266 A5 JP2016130266 A5 JP 2016130266A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
macular degeneration
composition according
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016083344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016130266A (ja
JP6378242B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016130266A publication Critical patent/JP2016130266A/ja
Publication of JP2016130266A5 publication Critical patent/JP2016130266A5/ja
Application granted granted Critical
Publication of JP6378242B2 publication Critical patent/JP6378242B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016083344A 2009-12-11 2016-04-19 黄斑変性の処置のための組成物および方法 Active JP6378242B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28574509P 2009-12-11 2009-12-11
US61/285,745 2009-12-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014255880A Division JP6063916B2 (ja) 2009-12-11 2014-12-18 黄斑変性の処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2016130266A JP2016130266A (ja) 2016-07-21
JP2016130266A5 true JP2016130266A5 (cg-RX-API-DMAC7.html) 2016-12-01
JP6378242B2 JP6378242B2 (ja) 2018-08-22

Family

ID=44145918

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012543284A Active JP5885670B2 (ja) 2009-12-11 2010-12-09 黄斑変性の処置のための組成物および方法
JP2014255880A Active JP6063916B2 (ja) 2009-12-11 2014-12-18 黄斑変性の処置のための組成物および方法
JP2016083344A Active JP6378242B2 (ja) 2009-12-11 2016-04-19 黄斑変性の処置のための組成物および方法
JP2016245212A Pending JP2017052799A (ja) 2009-12-11 2016-12-19 黄斑変性の処置のための組成物および方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012543284A Active JP5885670B2 (ja) 2009-12-11 2010-12-09 黄斑変性の処置のための組成物および方法
JP2014255880A Active JP6063916B2 (ja) 2009-12-11 2014-12-18 黄斑変性の処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016245212A Pending JP2017052799A (ja) 2009-12-11 2016-12-19 黄斑変性の処置のための組成物および方法

Country Status (4)

Country Link
US (4) US9814701B2 (cg-RX-API-DMAC7.html)
JP (4) JP5885670B2 (cg-RX-API-DMAC7.html)
CA (1) CA2782015C (cg-RX-API-DMAC7.html)
WO (1) WO2011072141A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2609659C (en) 2005-05-26 2014-01-28 Neuron Systems, Inc. Azanaphthalenes, compositions and methods for treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
HK1217325A1 (zh) 2012-12-20 2017-01-06 奥尔德拉医疗公司 迫位原醇
AU2014209387B2 (en) 2013-01-23 2018-11-01 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
RU2015126015A (ru) * 2013-01-25 2017-03-03 Альдейра Терапьютикс, Инк. Новые улавливатели в лечении макулодистрофии
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CA3016759A1 (en) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
CA3022665A1 (en) * 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2018170476A1 (en) * 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020068986A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
US20220118002A1 (en) 2019-03-05 2022-04-21 Cornell University Compositions of matter with activity to remove lipofuscin from retinal cells
WO2020198064A1 (en) * 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
WO2022092896A1 (ko) * 2020-10-29 2022-05-05 주식회사 피노바이오 시신경 보호 대상인 환자에게 점안제로 투여하기 위한 약학 조성물

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU50906A1 (ru) 1935-12-20 1936-11-30 А.И. Бурляев Веретено дл пр дильных машин
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
JPS6192592A (ja) 1984-10-12 1986-05-10 Norin Suisansyo Shokuhin Sogo Kenkyusho 分岐サイクロデキストリンの製造方法
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1992007056A1 (en) 1990-10-22 1992-04-30 Bausch & Lomb Incorporated Method and composition for cleaning contact lenses
AU641052B2 (en) 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
JP2746832B2 (ja) 1993-05-14 1998-05-06 大鵬薬品工業株式会社 眼局所抗アレルギー剤
GB9318431D0 (en) 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
US5767109A (en) 1993-10-20 1998-06-16 Sanchez; Robert A. Complexing urushiols
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
JPH08175985A (ja) 1994-12-26 1996-07-09 Lion Corp 点眼剤
JP3297969B2 (ja) 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
FR2742053B1 (fr) 1995-12-06 1998-03-06 Chauvin Lab Sa Compositions pharmaceutiques a base de mequitazine
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
AU723758B2 (en) 1996-08-01 2000-09-07 Dow Agrosciences Llc 4-substituted quinoline derivatives having fungicidal activity
TR199900228T2 (xx) 1996-08-06 1999-03-22 Pfizer Inc. �kameli/katk�l� pirido-veya pirimido-i�eren 6,6-veya 6,7-bisiklik t�revler.
ATE336485T1 (de) 1997-05-02 2006-09-15 Schering Ag Substituierte heterocyclen und deren verwendung in arzneimitteln
JPH10306022A (ja) 1997-05-06 1998-11-17 Lion Corp 点眼剤
GB2327672A (en) 1997-07-23 1999-02-03 Merck & Co Inc 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
US6245769B1 (en) 1997-09-02 2001-06-12 Dupont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP3568108B2 (ja) 1999-07-28 2004-09-22 松下電器産業株式会社 デジタル地図の位置情報伝達方法とそれを実施する装置
JP2003514019A (ja) 1999-11-15 2003-04-15 スミスクライン・ビーチャム・コーポレイション カルベジロールメタンスルホン酸塩
AU1735001A (en) 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2001318350A (ja) 2000-05-11 2001-11-16 Lion Corp コンタクトレンズ用溶液
JP4748289B2 (ja) 2000-06-23 2011-08-17 ライオン株式会社 点眼剤、眼科用組成物及び吸着抑制方法
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
CA2416228C (en) * 2002-01-15 2010-07-13 Olsonet Communications Corporation Communication nodes for use with a wireless ad-hoc communication network
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040198828A1 (en) 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
JP2006520393A (ja) 2003-03-14 2006-09-07 ユニバーシティ オブ ワシントン レチノイド補充物およびオプシンアゴニスト、ならびにそれらの使用法
EP2292239A3 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
JP2005132834A (ja) 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
TWI344961B (en) 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
RU2006118325A (ru) 2003-10-27 2007-12-10 Астеллас Фарма Инк. (Jp) Производные пиразина и их фармацевтическое применение
AU2004293105B2 (en) 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
JP2005187407A (ja) 2003-12-25 2005-07-14 Lion Corp アレルギー眼疾患用眼科組成物
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
US20080176952A1 (en) 2004-02-17 2008-07-24 Rando Robert R Management of Ophthalmologic Disorders, Including Macular Degeneration
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk IgE抗体抑制剤および食品
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
JP2008518913A (ja) 2004-10-28 2008-06-05 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体のピリミジン及びキノリン増強因子
WO2006077821A1 (ja) 2005-01-19 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. アルドステロン受容体調節剤としての芳香族スルホン化合物
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN1830964B (zh) 2005-03-11 2011-06-15 中国科学院上海药物研究所 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途
WO2006122183A2 (en) 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
CA2609659C (en) 2005-05-26 2014-01-28 Neuron Systems, Inc. Azanaphthalenes, compositions and methods for treating retinal disease
EP1967186B1 (en) 2005-12-27 2015-03-11 Lion Corporation Composition for soft contact lens and adsorption suppressing method
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
JP4466875B2 (ja) 2006-04-05 2010-05-26 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
JP5290147B2 (ja) 2006-04-14 2013-09-18 プラナ バイオテクノロジー リミティッド 加齢黄斑変性症(amd)の処置方法
JP5194218B2 (ja) 2006-06-05 2013-05-08 株式会社メニコンネクト 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
CN101611009A (zh) 2006-07-25 2009-12-23 伊维沃制药股份有限公司 喹啉衍生物
MX2009001770A (es) 2006-08-14 2009-02-25 Schering Corp Sales de 5-(l(s)-amino-2-hidroxietil)-n-[(2.4-difluorofenil)-metil ]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida.
NZ575171A (en) 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
TW200823187A (en) 2006-10-24 2008-06-01 Wyeth Corp Benzodioxane derivatives and uses thereof
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US20080241256A1 (en) 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
US8490764B2 (en) 2007-05-30 2013-07-23 Margaret Simester Portable storage and changing station
US20090118503A1 (en) 2007-06-20 2009-05-07 Kevin Sprott Faah inhibitors
MX337100B (es) 2007-10-05 2016-02-11 Acucela Inc Compuestos alcoxi para el tratamiento de enfermedades.
US8324270B2 (en) 2008-02-11 2012-12-04 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
US20120108585A1 (en) 2008-08-12 2012-05-03 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
EP2340242A4 (en) 2008-10-22 2012-04-04 Acucela Inc COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
CA2754996A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
WO2010133672A1 (en) 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
US20110105450A1 (en) 2009-06-05 2011-05-05 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
WO2010148351A1 (en) 2009-06-18 2010-12-23 Cylene Pharmaceuticals, Inc. Rhodanines and related heterocycles as kinase inhibitors
EP2477594A4 (en) 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
WO2011078204A1 (ja) 2009-12-24 2011-06-30 浜理薬品工業株式会社 高脂血症の予防または治療剤、および抗疲労剤
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
WO2011116066A1 (en) 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
JP2011203665A (ja) 2010-03-26 2011-10-13 Ophtecs Corp コンタクトレンズの白濁解消用製剤及び白濁解消方法
SG10201506870PA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Salts of lorcaserin with optically active acids
CA2816420C (en) 2010-10-29 2018-01-16 Najib Babul Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
EP3208263A1 (en) 2011-01-12 2017-08-23 VentiRx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
WO2012100142A2 (en) 2011-01-20 2012-07-26 Cornell University Treatments for retinal disorders
WO2012105887A1 (en) 2011-01-31 2012-08-09 Tim Bowden Active principle for mitigating undesired medical conditions
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
CA2851643A1 (en) 2011-10-13 2013-04-18 Thomas Gadek Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions
US20130190500A1 (en) 2011-12-12 2013-07-25 Neuron Systems, Inc. Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
US9817701B2 (en) 2011-12-12 2017-11-14 International Business Machines Corporation Threshold computing in a distributed computing system
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
GB201200192D0 (en) 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
EP2879683B1 (en) 2012-08-01 2020-01-22 Lewis and Clark Pharmaceuticals, Inc. N-alkyl-alkynyladenosine-5-uronamide compounds as agonists of a2a receptor
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
HK1217325A1 (zh) 2012-12-20 2017-01-06 奥尔德拉医疗公司 迫位原醇
AU2014209387B2 (en) 2013-01-23 2018-11-01 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US9833460B2 (en) 2013-01-23 2017-12-05 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation
RU2015126015A (ru) 2013-01-25 2017-03-03 Альдейра Терапьютикс, Инк. Новые улавливатели в лечении макулодистрофии
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
US9713330B1 (en) 2013-03-15 2017-07-25 Deuteria Agrochemicals, Llc Deuterium-enriched aldehydes
WO2015002893A1 (en) 2013-07-02 2015-01-08 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
EP3151818A4 (en) 2014-06-04 2018-05-30 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
US10736842B2 (en) 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
NO2721710T3 (cg-RX-API-DMAC7.html) 2014-08-21 2018-03-31
AU2015312134A1 (en) 2014-09-02 2017-03-23 Bhupinder Singh Deuterated or a non-deuterated molecule and pharmaceutical formulations
TW201628622A (zh) 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
US10363231B2 (en) 2014-11-24 2019-07-30 Case Western Reserve University Compounds and methods of treating ocular disorders
US9953187B2 (en) 2014-11-25 2018-04-24 Honeywell International Inc. System and method of contextual adjustment of video fidelity to protect privacy
EP3283486B1 (en) 2015-04-15 2022-07-27 BeiGene, Ltd. Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
EP3337470A4 (en) 2015-08-21 2019-02-27 Aldeyra Therapeutics, Inc. ALDEHYDE CONJUGATES AND USES THEREOF
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
CA3016759A1 (en) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US11865113B2 (en) 2016-06-06 2024-01-09 Lipidio Pharmaceuticals Inc. Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH)
CA3032609A1 (en) 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
MX2019001722A (es) 2016-08-22 2019-07-04 Aldeyra Therapeutics Inc Compuestos de captura de aldehido y usos de los mismos.
AU2017336765B2 (en) 2016-09-28 2023-06-08 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
JP7017563B2 (ja) 2016-10-05 2022-02-08 ミトブリッジ,インコーポレーテッド Pparアゴニスト化合物の結晶性および塩形態
EP3525885B1 (en) 2016-10-12 2022-01-26 PS Therapy Ltd. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
GB2556082A (en) 2016-11-18 2018-05-23 Warneford Healthcare Ltd Ophthalmic composition
WO2018170476A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US10664688B2 (en) 2017-09-20 2020-05-26 Google Llc Systems and methods of detecting and responding to a visitor to a smart home environment
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
EP3724866A1 (en) 2017-12-14 2020-10-21 Lutron Technology Company LLC Privacy mode for a wireless audio device
WO2020018498A1 (en) 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US10915995B2 (en) 2018-09-24 2021-02-09 Movidius Ltd. Methods and apparatus to generate masked images based on selective privacy and/or location tracking
WO2020068986A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
US20210317385A1 (en) 2018-10-02 2021-10-14 Aldeyra Therapeutics, Inc. Contact lens solutions and kits
US20220133697A1 (en) 2018-12-05 2022-05-05 Aldeyra Therapeutics, Inc. Injectable formulations
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
KR20220062617A (ko) 2019-09-13 2022-05-17 알데이라 테라퓨틱스, 아이엔씨. 메토트렉세이트의 안과용 제형
WO2021195211A1 (en) 2020-03-24 2021-09-30 Aldeyra Therapeutics, Inc. Quinoline compounds for treating respiratory disorders and viral infections
WO2021211625A1 (en) 2020-04-13 2021-10-21 Aldeyra Therapeutics, Inc. Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
WO2021248031A1 (en) 2020-06-04 2021-12-09 Aldeyra Therapeutics, Inc. Dry eye disease biomarkers and their use for treatment
CN112541870A (zh) 2020-12-07 2021-03-23 北京大米科技有限公司 一种视频处理的方法、装置、可读存储介质和电子设备
WO2022150580A1 (en) 2021-01-07 2022-07-14 Aldeyra Therapeutics, Inc. Treatment of dry eye disease
US20220211691A1 (en) 2021-01-07 2022-07-07 Aldeyra Therapeutics, Inc. Treatment of dry eye disease
CN112800947A (zh) 2021-01-27 2021-05-14 上海电气集团股份有限公司 视频监控方法、系统、电子设备及存储介质
KR20240032926A (ko) 2021-07-02 2024-03-12 알데이라 테라퓨틱스, 아이엔씨. 헤테로사이클릭 알데하이드 트랩핑 화합물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2016130266A5 (cg-RX-API-DMAC7.html)
JP2015057437A5 (cg-RX-API-DMAC7.html)
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
JP2018024670A5 (cg-RX-API-DMAC7.html)
CN109415406A (zh) 羊毛甾醇前药化合物及其制备方法和应用
MX2021005295A (es) Tolilos sustituidos como fungidas.
JP2017222697A5 (cg-RX-API-DMAC7.html)
MX2023003068A (es) Oxadiazoles fungicidas.
JP2016506958A5 (cg-RX-API-DMAC7.html)
JP2016505614A5 (cg-RX-API-DMAC7.html)
JP2014521688A5 (cg-RX-API-DMAC7.html)
JP2017523143A5 (cg-RX-API-DMAC7.html)
JP2016515561A5 (cg-RX-API-DMAC7.html)
JP2021502388A5 (cg-RX-API-DMAC7.html)
JP2016507575A5 (cg-RX-API-DMAC7.html)
JP2017504635A5 (cg-RX-API-DMAC7.html)
JP2016531126A5 (cg-RX-API-DMAC7.html)
CN109563060A (zh) Ido1抑制剂及其制备方法和应用
JP2020097577A5 (cg-RX-API-DMAC7.html)
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
JP2018521056A5 (cg-RX-API-DMAC7.html)
JP2015535257A5 (cg-RX-API-DMAC7.html)
JP2016503403A5 (cg-RX-API-DMAC7.html)
WO2019099564A8 (en) Novel imidazopyrimidine compounds and uses thereof